BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Nilvanstomig readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of Nilvanstomig\, from ClinicalTrials.gov es
 timates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT06903377-2822@assetmemo.bio
DTSTAMP:20261121T004530Z
DTSTART;VALUE=DATE:20270430
DTEND;VALUE=DATE:20270501
SUMMARY:Nilvanstomig: Phase 1/2 readout est. (NCT06903377)
DESCRIPTION:Nilvanstomig\, phase 1/2\, Non-Small Cell Lung Cancer.\nStudy: 
 Study of ZG005 Combined With Gecacitinib in Patients With Advanced Non-Sma
 ll Cell Lung Cancer\nEstimated primary completion: April 2027. This is a C
 linicalTrials.gov estimate\, not a confirmed readout date\, and it can mov
 e.\nDrug page: https://assetmemo.bio/drug/nilvanstomig#upcoming-events\nRe
 gistry record: https://clinicaltrials.gov/study/NCT06903377
URL:https://assetmemo.bio/drug/nilvanstomig#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06883526-2822@assetmemo.bio
DTSTAMP:20261121T004530Z
DTSTART;VALUE=DATE:20270430
DTEND;VALUE=DATE:20270501
SUMMARY:Nilvanstomig: Phase 1/2 readout est. (NCT06883526)
DESCRIPTION:Nilvanstomig\, phase 1/2.\nStudy: Study of ZG005 in Combination
  With Gecacitinib in Patients With Relapsed or Refractory Lymphoma\nEstima
 ted primary completion: April 2027. This is a ClinicalTrials.gov estimate\
 , not a confirmed readout date\, and it can move.\nDrug page: https://asse
 tmemo.bio/drug/nilvanstomig#upcoming-events\nRegistry record: https://clin
 icaltrials.gov/study/NCT06883526
URL:https://assetmemo.bio/drug/nilvanstomig#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06938880-2822@assetmemo.bio
DTSTAMP:20261121T004530Z
DTSTART;VALUE=DATE:20270531
DTEND;VALUE=DATE:20270601
SUMMARY:Nilvanstomig: Phase 1/2 readout est. (NCT06938880)
DESCRIPTION:Nilvanstomig\, phase 1/2.\nStudy: Study of ZGGS18 in Combinatio
 n With ZG005 in Patients With Advanced Solid Tumors\nEstimated primary com
 pletion: May 2027. This is a ClinicalTrials.gov estimate\, not a confirmed
  readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/ni
 lvanstomig#upcoming-events\nRegistry record: https://clinicaltrials.gov/st
 udy/NCT06938880
URL:https://assetmemo.bio/drug/nilvanstomig#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06927687-2822@assetmemo.bio
DTSTAMP:20261121T004530Z
DTSTART;VALUE=DATE:20270531
DTEND;VALUE=DATE:20270601
SUMMARY:Nilvanstomig: Phase 2 readout est. (NCT06927687)
DESCRIPTION:Nilvanstomig\, phase 2.\nStudy: Study of ZG005 in Patients With
  Advanced Solid Tumors\nEstimated primary completion: May 2027. This is a 
 ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can mo
 ve.\nDrug page: https://assetmemo.bio/drug/nilvanstomig#upcoming-events\nR
 egistry record: https://clinicaltrials.gov/study/NCT06927687
URL:https://assetmemo.bio/drug/nilvanstomig#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07080216-2822@assetmemo.bio
DTSTAMP:20261121T004530Z
DTSTART;VALUE=DATE:20270831
DTEND;VALUE=DATE:20270901
SUMMARY:Nilvanstomig: Phase 1/2 readout est. (NCT07080216)
DESCRIPTION:Nilvanstomig\, phase 1/2.\nStudy: Study of ZG005 in Combination
  With Gecacitinib in Participants With Advanced Cervical Cancer\nEstimated
  primary completion: August 2027. This is a ClinicalTrials.gov estimate\, 
 not a confirmed readout date\, and it can move.\nDrug page: https://assetm
 emo.bio/drug/nilvanstomig#upcoming-events\nRegistry record: https://clinic
 altrials.gov/study/NCT07080216
URL:https://assetmemo.bio/drug/nilvanstomig#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07038096-2822@assetmemo.bio
DTSTAMP:20261121T004530Z
DTSTART;VALUE=DATE:20270930
DTEND;VALUE=DATE:20271001
SUMMARY:Nilvanstomig: Phase 1/2 readout est. (NCT07038096)
DESCRIPTION:Nilvanstomig\, phase 1/2.\nStudy: ZG006 and ZG005 in Participan
 ts With Small Cell Lung Cancer or Neuroendocrine Carcinoma\nEstimated prim
 ary completion: September 2027. This is a ClinicalTrials.gov estimate\, no
 t a confirmed readout date\, and it can move.\nDrug page: https://assetmem
 o.bio/drug/nilvanstomig#upcoming-events\nRegistry record: https://clinical
 trials.gov/study/NCT07038096
URL:https://assetmemo.bio/drug/nilvanstomig#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07142837-2822@assetmemo.bio
DTSTAMP:20261121T004530Z
DTSTART;VALUE=DATE:20271031
DTEND;VALUE=DATE:20271101
SUMMARY:Nilvanstomig: Phase 1/2 readout est. (NCT07142837)
DESCRIPTION:Nilvanstomig\, phase 1/2.\nStudy: Study of ZG005 in Combination
  With Gecacitinib and Chemotherapy for Participants With Advanced Solid Tu
 mors\nEstimated primary completion: October 2027. This is a ClinicalTrials
 .gov estimate\, not a confirmed readout date\, and it can move.\nDrug page
 : https://assetmemo.bio/drug/nilvanstomig#upcoming-events\nRegistry record
 : https://clinicaltrials.gov/study/NCT07142837
URL:https://assetmemo.bio/drug/nilvanstomig#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07099547-2822@assetmemo.bio
DTSTAMP:20261121T004530Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Nilvanstomig: Phase 2 readout est. (NCT07099547)
DESCRIPTION:Nilvanstomig\, phase 2.\nStudy: Study of ZG005 in Combination W
 ith Platinum-Based Chemotherapy in Participants With Advanced Biliary Trac
 t Carcinoma\nEstimated primary completion: December 2027. This is a Clinic
 alTrials.gov estimate\, not a confirmed readout date\, and it can move.\nD
 rug page: https://assetmemo.bio/drug/nilvanstomig#upcoming-events\nRegistr
 y record: https://clinicaltrials.gov/study/NCT07099547
URL:https://assetmemo.bio/drug/nilvanstomig#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07813572-2822@assetmemo.bio
DTSTAMP:20261121T004530Z
DTSTART;VALUE=DATE:20310930
DTEND;VALUE=DATE:20311001
SUMMARY:Nilvanstomig: Phase 3 readout est. (NCT07813572)
DESCRIPTION:Nilvanstomig\, phase 3\, Hepatocellular Carcinoma.\nStudy: ZG00
 5 Plus Bevacizumab vs Sintilimab Plus Bevacizumab as First-Line Therapy fo
 r Advanced Hepatocellular\nEstimated primary completion: September 2031. T
 his is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and 
 it can move.\nDrug page: https://assetmemo.bio/drug/nilvanstomig#upcoming-
 events\nRegistry record: https://clinicaltrials.gov/study/NCT07813572
URL:https://assetmemo.bio/drug/nilvanstomig#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07833839-2822@assetmemo.bio
DTSTAMP:20261121T004530Z
DTSTART;VALUE=DATE:20311031
DTEND;VALUE=DATE:20311101
SUMMARY:Nilvanstomig: Phase 3 readout est. (NCT07833839)
DESCRIPTION:Nilvanstomig\, phase 3.\nStudy: ZG005 Plus Etoposide and Cispla
 tin vs. Etoposide and Cisplatin as First-Line Treatment for Advanced Neuro
 endocrine Carcinoma\nEstimated primary completion: October 2031. This is a
  ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can m
 ove.\nDrug page: https://assetmemo.bio/drug/nilvanstomig#upcoming-events\n
 Registry record: https://clinicaltrials.gov/study/NCT07833839
URL:https://assetmemo.bio/drug/nilvanstomig#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
